Published in Nat Med on July 01, 2000
A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection | NCT00038272
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) | NCT00120419
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
HIV-associated chronic immune activation. Immunol Rev (2013) 1.38
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol (2005) 1.05
Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res (2006) 0.99
Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. Antimicrob Agents Chemother (2005) 0.97
Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis (2009) 0.95
De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans. PLoS Pathog (2012) 0.94
Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther (2012) 0.93
Host-based antipoxvirus therapeutic strategies: turning the tables. J Clin Invest (2005) 0.85
In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 0.83
Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant (2007) 0.83
Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS (2016) 0.82
Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J Virol (2001) 0.81
CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity (2016) 0.81
A computational study identifies HIV progression-related genes using mRMR and shortest path tracing. PLoS One (2013) 0.79
Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice. Clin Exp Immunol (2001) 0.77
Taking aim at HIV replication. Nat Med (2000) 0.77
A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res Ther (2006) 0.76
Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg (2011) 0.76
Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. World J Gastroenterol (2014) 0.76
Anti-rheumatoid Activity of Secondary Metabolites Produced by Endophytic Chaetomium globosum. Front Microbiol (2016) 0.75
Update on kidney transplantation in human immunodeficiency virus infected recipients. World J Nephrol (2016) 0.75
Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study. Dermatol Pract Concept (2017) 0.75
Inhibition of HIV replication in vitro by clinical immunosuppressants and chemotherapeutic agents. Cell Biosci (2013) 0.75
Anti-proliferative therapy for HIV cure: a compound interest approach. Sci Rep (2017) 0.75
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol (2000) 8.49
Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med (1995) 4.65
Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity. J Exp Med (1983) 4.47
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
A molecular basis for MHC class II--associated autoimmunity. Science (1988) 3.75
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med (1990) 2.93
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science (1994) 2.92
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A (1987) 2.77
Immunopathogenic mechanisms of HIV infection. Ann Intern Med (1996) 2.61
Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science (1992) 2.60
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 2.54
Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol (1998) 2.33
T cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule, TL. Science (2001) 2.30
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci U S A (1988) 2.30
Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations. J Exp Med (1983) 2.16
NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 2.15
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
T cell recognition as the target for immune intervention in autoimmune disease. Cell (1989) 2.04
Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex. J Exp Med (1985) 1.92
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med (1988) 1.89
Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 1.80
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor. Proc Natl Acad Sci U S A (1988) 1.75
Identical V beta T-cell receptor genes used in alloreactive cytotoxic and antigen plus I-A specific helper T cells. Nature (1985) 1.74
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.73
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS (1999) 1.73
A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s). J Exp Med (1988) 1.71
Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2000) 1.69
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med (1993) 1.67
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.66
The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today (1989) 1.66
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet (1998) 1.62
Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production. J Exp Med (1997) 1.57
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci U S A (1993) 1.54
Cytotoxic T cell clone-specific monoclonal antibodies used to select clonotypic antigen-specific cytotoxic T cells. Eur J Immunol (1985) 1.52
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity (2002) 1.49
Transmembrane signalling via the T11-dependent pathway of human T cell activation. Evidence for the involvement of 1,2-diacylglycerol and inositol phosphates. Eur J Immunol (1987) 1.49
Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activation. Proc Natl Acad Sci U S A (1987) 1.47
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.46
Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest (1997) 1.46
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J Exp Med (1992) 1.45
Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A (1996) 1.44
Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci U S A (1996) 1.39
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis (2016) 1.39
Selection and characterization of monoclonal antibodies to the idiotype-like structure of an interleukin-2-producing human leukemia T-cell line. Int J Cancer (1985) 1.38
Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol (2001) 1.38
Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans. Immunol Rev (1989) 1.33
Modulation of surface T11 molecules induced by monoclonal antibodies: analysis of the functional relationship between antigen-dependent and antigen-independent pathways of human T cell activation. Eur J Immunol (1986) 1.33
Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med (2001) 1.32
A polymorphic microsatellite in the tumor necrosis factor alpha promoter identifies an allele unique to the NZW mouse strain. J Exp Med (1990) 1.31
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med (1993) 1.29
Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin Immunol Immunopathol (1997) 1.29
Mouse mammary tumor virus: immunological interplays between virus and host. Adv Immunol (1997) 1.29
Clonal heterogeneity in the requirement for T3, T4, and T8 molecules in human cytolytic T lymphocyte function. J Exp Med (1984) 1.29
Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med (1994) 1.28
Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia (2004) 1.26
CD3+ WT31- peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the alpha/beta heterodimer. Eur J Immunol (1987) 1.23
Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J Immunol (1999) 1.22
Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur J Immunol (2001) 1.21
Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation. J Exp Med (1987) 1.19
Characterization of cloned cytotoxic lymphocytes with NK-like activity. J Immunol (1983) 1.18
The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol (2010) 1.14
Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development. Mucosal Immunol (2010) 1.14
Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med (1994) 1.09
Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins. Proc Natl Acad Sci U S A (1994) 1.07
Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol (2000) 1.07
CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med (1998) 1.07
Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol (2003) 1.06
Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. J Immunol (1997) 1.04
Infection of CD8+ T lymphocytes with HIV. Requirement for interaction with infected CD4+ cells and induction of infectious virus from chronically infected CD8+ cells. J Immunol (1991) 1.04
Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol (1998) 1.03
Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes. J Immunol (1991) 1.03
Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. Clin Exp Immunol (1998) 1.01
Surface markers of cloned human T cells with helper or suppressor activity on pokeweed mitogen-driven B cell differentiation. Eur J Immunol (1982) 1.01
Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS (1999) 0.99
Frequent coexpression of cytolytic activity and lymphokine production among human T lymphocytes. Production of B cell growth factor and interleukin 2 by T8+ and T4+ cytolytic clones. Eur J Immunol (1984) 0.99
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A (1995) 0.99
Stimulation and proliferation of CD4+ peripheral blood T lymphocytes induced by an anti-CD4 monoclonal antibody. Eur J Immunol (1988) 0.98
Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation. Eur J Immunol (1994) 0.98
Signal transducing mechanisms involved in human T cell activation via surface T44 molecules. Comparison with signals transduced via the T cell receptor complex. Eur J Immunol (1986) 0.98
Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J Virol (1997) 0.97
Assignment of human natural killer (NK)-like cells to the T cell lineage. Single allospecific T cell clones lyse specific or NK-sensitive target cells via distinct recognition structures. Eur J Immunol (1984) 0.97
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS (2000) 0.96
Different types of effector cells involved in non-mhc-restricted cytolytic activity. Ann Inst Pasteur Immunol (1988) 0.96